Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Medicines on shelf - Prasanth - stock.adobe.com.jpg
Rising Costs of Biologics for Plaque Psoriasis Highlight Savings Potential

April 24th 2025

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.

Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com
Icotrokinra Shows Clear Skin in 75% of Adolescents With Plaque Psoriasis in Phase 3 Trial

April 10th 2025

Psoriasis oral treatment | Image credit: Pawel - stock.adobe.com
Women Have Lower Drug Survival With Biologics for Psoriasis, Including IL-17 and IL-23 Inhibitors

April 7th 2025

Psoriasis treatment concept | Sviatlana - stock.adobe.com
Tildrakizumab Effective Up to Nearly 3 Years Regardless of BSA Affected, Obesity

April 1st 2025

Bimekizumab | Image credit: luchschenF - stock.adobe.com
Bimekizumab Reduces Inflammation, Cardiovascular Risk

March 21st 2025

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
April 25th 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
April 25th 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

image of doctor and pregnant woman
June 9th 2023

Review Suggests Psoriasis Biologics Not Linked With Adverse Outcomes in Pregnant Patients

Gianna Melillo
Findings are based on a meta-analysis of 51 studies and 739 pregnancies.
CLOSE UP Woman with big red scaly rash suffering from elbow psoriatic arthritis: © helivideo - stock.adobe.com
June 3rd 2023

Review Identifies Criteria Used to Define Anti–TNF-α Failure in Patients With Psoriasis

Gianna Melillo
It’s estimated around 20% of patients will discontinue their first course of anti–tumor necrosis factor-α (anti–TNF-α) and rates increase over time
Syringe and vials
June 2nd 2023

Study Compares Real-world Adverse Events of Methotrexate, Biologics for Psoriasis

Gianna Melillo
Although methotrexate was linked with a higher risk of anemia, it carried risks of kidney and other serious infections similar to those of biologics.
image of psoriasis
May 25th 2023

Nonmelanoma Skin Cancer Risks Are Higher When Using Methotrexate for Psoriasis: Study

Gianna Melillo
Patients with psoriasis taking methotrexate are nearly 3 times as likely to develop non-melanoma skin cancer than patients not taking the treatment.
image of a biologic
May 20th 2023

Biologic Switching Common Among Patients With Psoriasis in Real-World Setting

Gianna Melillo
After 1 year, overall treatment switch rates were 14.4%, while after 2 years, switch rates were 26%.
Doctor writing word Psoriasis with marker, Medical concept: © Michail Petrov - stock.adobe.com
May 17th 2023

Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting

Gianna Melillo
Strict inclusion and exclusion criteria in clinical trials means findings on health-related quality of life (HRQOL) may not be generalizable to the real-world setting.
Close-up woman touches herself. Neck, back, spine. Psoriasis skin, eczema, rash and other skin diseases. A woman hides her face, she is ashamed of her autoimmune genetic disease. Imperfect beauty: © stockmaster - stock.adobe.com
May 10th 2023

Drugs Affecting the IL-23 Pathway May Lower Risk of Psoriatic, Inflammatory Arthritis From Psoriasis

Gianna Melillo
Findings show these drugs were linked with a lower risk of progression to inflammatory arthritis compared with tumor necrosis factor inhibitors, although more research is needed to confirm the finding.
Teenage Girl Sitting In Bedroom Scratching Arm: © Daisy Daisy - stock.adobe.com
May 5th 2023

Study Outlines Patient-Reported Outcomes Among Pediatric Patients With Psoriasis

Gianna Melillo
Approximately one quarter of patients who have psoriasis experience disease onset before adulthood.
Psoriasis
April 25th 2023

In Elderly, Psoriasis Heightens Risk of Malignancy

Jared Kaltwasser
Older people with psoriasis had a roughly 50% higher risk of being diagnosed with a malignancy, investigators found.
image of psoriasis
April 25th 2023

Cost Burden of GPP Much Higher Than Psoriasis Vulgaris, Study Finds

Jared Kaltwasser
Ten-year mean costs associated with psoriasis-related health care visits were 10 times higher for patients with generalized pustular psoriasis (GPP).
Itching in a woman: © RFBSIP - stock.adobe.com
April 14th 2023

Biologics May Prevent PsA in Patients With Psoriasis

Gianna Melillo
Because biologics are used to treat both conditions, researchers hypothesized they may be helpful to prevent psoriatic arthritis (PsA).
Tildrakizumab monoclonal antibody drug. Used in treatment of psoriasis. Targets interleukin-23. Generic name and stylized antibody representation: © molekuul.be- stock.adobe.com
April 12th 2023

Trial Results Show Tildrakizumab Is Safe, Effective for Psoriasis Across Ages

Gianna Melillo
This analysis pooled data from the reSURFACE 1 and reSURFACE 2 trials of tildrakizumab use among patients with moderate to severe plaque psoriasis.
image of dermatologist visit
March 24th 2023

Examining Health Care Disparities in Psoriasis and Other Skin Diseases

Pearl Steinzor
Minority patients with skin diseases such as psoriasis often experience racial and ethnic barriers to care, a recent review found.
Image of an online survey: Tierney - stock.adobe.com
March 21st 2023

Race, Ethnicity May Not Affect Biologic Prescribing Patterns for Psoriasis

Jared Kaltwasser
Dermatologists recommended biologics at similar rates in scenarios describing Black, Hispanic, and White patients with moderate to severe psoriasis.
image of hands with psoriatic arthritis
March 18th 2023

Polypharmacy Is Significantly Higher in Patients With Psoriatic Arthritis

Lana Pine
Polypharmacy was significantly higher in patients with psoriatic arthritis when compared with controls, according to a new study.
Image of a mobile health app: adam - stock.adobe.com
March 14th 2023

Accurate Remote Assessment of Psoriasis Possible From Patient Photographs, Questionnaire Responses, Study Finds

Jared Kaltwasser
In this new analysis, investigators found significant agreement between in-person and remote assessments.
Final Thoughts on Psoriasis Across Skin Types
February 28th 2023

Final Thoughts on Psoriasis Across Skin Types

A panel of experts provide their final thoughts on treating psoriasis across all skin phototypes.
Health Equity Across All Skin Phototypes
February 28th 2023

Health Equity Across All Skin Phototypes

A panel of experts provide their final thoughts on treating psoriasis across all skin phototypes.
Incentivizing Patient Use of Digital Health Tools
February 28th 2023

Incentivizing Patient Use of Digital Health Tools

Maria Lopes, MD, MS, and Amy McMichael, MD, discuss how payers can incentivize patients’ use of digital health tools to monitor the success or failure of treatment.
Psorcast: A Digital Health Tool for Patients
February 21st 2023

Psorcast: A Digital Health Tool for Patients

Amy McMichael, MD, provides an overview of the Psorcast app and how it can benefit treatment adherence for patients.
Addressing Disparities in Care for Psoriasis
February 21st 2023

Addressing Disparities in Care for Psoriasis

Bruce Sherman, MD, FCCP, FACOEM, and Maria Lopes, MD, MS, discuss how organizations can address disparities in care for psoriasis.
Challenges Across Skin Phenotypes
February 14th 2023

Challenges Across Skin Phenotypes

Maria Lopes, MD, MS, reviews some challenges surrounding access to care, patient education, and financial burdens associated with psoriasis across skin phototypes.
Ensuring Equal Face-to-Face Provider-Interaction Time Among Patients
February 14th 2023

Ensuring Equal Face-to-Face Provider-Interaction Time Among Patients

Amy McMichael, MD, discusses ways to ensure patients of all races and ethnicities are experiencing the same level of quality face-to-face interactions with their providers.
Site Logo
February 11th 2023

Migraine More Common in Patients With Psoriasis, Say Findings

Jaime Rosenberg
The subset of patients with psoriatic arthritis had the highest odds ratio of migraine.
picture of depressed person
February 10th 2023

Survey: Depression Worsened Psoriasis Symptoms, QOL During COVID-19 Lockdown

Jaime Rosenberg
Findings from the survey suggest that certain symptoms of depression could help identify patients vulnerable to both worsening psoriasis symptoms and disease-related quality of life (QoL).
Educating Providers and Improving Early Diagnosis
February 7th 2023

Educating Providers and Improving Early Diagnosis

Maria Lopes, MD, MS, reviews how to educate providers on the risks and burdens of psoriasis and how to improve early diagnosis and treatment for all skin phototypes and ethnicities.
Financial Burden on Psoriasis Patients
February 7th 2023

Financial Burden on Psoriasis Patients

Bruce Sherman, MD, FCCP, FACOEM, underlines how to support patients financially to afford therapies and maintain adherence.
Image of a lot of people
February 4th 2023

Common PsA Symptoms Negatively Impact Quality of Life

Jared Kaltwasser
A study attempted to see how symptoms affect quality of life after adjusting for confounding factors.
Image of different emotions
February 1st 2023

Prevalence of Mental Health Comorbidities in Psoriasis Probed in New Study

Jared Kaltwasser
The exact reasons for the links are not yet clear, although some evidence suggests inflammation plays a role.
Costs and Burdens of Psoriasis
January 31st 2023

Costs and Burdens of Psoriasis

Amy McMichael, MD, and Maria Lopes, MD, MS, review the major differences in quality of life, the impact on patients, and the costs and burdens associated with absenteeism or presentism.
<12345678
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo